Clinical and prognostic significance of mutant-allele tumor heterogeneity in thyroid papillary carcinoma

doi:10.3877/cma.j.issn.1674-0785.2019.11.007

Abstract

Abstract:

Objective

To investigate the clinical significance of mutant-allele tumor heterogeneity (MATH) levels in papillary thyroid carcinoma (PTC).

Methods

The sequencing data and clinical data of PTC were downloaded from the public data sets of The Cancer Genome Atlas (TCGA) and preprocessed. The correlation between MATH and clinicopathological features of PTC was analyzed. Kaplan-Meier survival analysis was used to verify the prognostic value of MATH in patients with PTC.

Results

MATH scores ranged from 2.57 to 93.72 in PTC patients, with an average of 29.45±16.19. The patients with an MATH score ≥ 29.45 were assigned to a high-MATH group, and those with an MATH score <29.45 were assigned to a low-MATH group. There was no significant difference in age, gender, tumor stage and BRAF genotype between the high-MATH group and low-MATH group (P>0.05). MATH was not a significant predictor of overall survival (OS) in patients with PTC (P=0.4595). Whereas in PTC patients with BRAF mutation, the OS in patients with a high MATH score was significantly worse than that in patients with a low MATH score (P=0.0252). In PTC patients with wild-type BRAF, the OS was significantly better in patients with a high MATH score than in those with a low MATH (P=0.0495).

Conclusion

MATH can predict the prognosis of PTC patients with wild type or mutant BRAF, which can be used to guide clinical treatment.

Key words: Mutation, Alleles, Tumor heterogeneity, Thyroid neoplasms, BRAF genotype, Overall survival

Siyuan Chen, Xiarong Hu, Chuping Xie. Clinical and prognostic significance of mutant-allele tumor heterogeneity in thyroid papillary carcinoma[J]. Chinese Journal of Clinicians(Electronic Edition), 2019, 13(11): 832-836.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2019.11.007

https://zhlcyszz.cma-cmc.com.cn/EN/Y2019/V13/I11/832

Figures/Tables 6

References 33

1	Jemal A, Bray F, Center MM, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2018, 68(6): 394-424.
2	杨雷, 郑荣寿, 王宁. 2010年中国甲状腺癌发病与死亡情况 [J]. 中华预防医学杂志, 2014, 48(8): 663-668.
3	俞敏, 龚巍巍, 罗胜兰. 甲状腺癌的流行现况及其危险因素 [J]. 中国预防医学杂志, 2013, (4): 317-322.
4	Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes [J]. Nature, 2013, 499(7457): 214-218.
5	Leite AKN, Cavalheiro BG, Kulcsar MA, et al. Deaths related to differentiated thyroid cancer: a rare but real event [J]. Arch Endocrinol Metab, 2017, 61(3): 222-227.
6	Robenshtok E, Nachalon Y, Benbassat C, et al. Disease severity at presentation in patients with disease-related mortality from differentiated thyroid cancer: implications for the 2015 ATA Guidelines [J]. Thyroid, 2017, 27(9): 1171-1176.
7	Shen X, Liu R, Xing M. A six-genotype genetic prognostic model for papillary thyroid cancer [J]. Endocr Relat Cancer, 2017, 24(1): 41-52.
8	Song YS, Park YJ. Genomic characterization of differentiated thyroid carcinoma [J]. Endocrinol Metab (Seoul), 2019, 34(1): 1-10.
9	Colombo C, Muzza M, Proverbio MC, et al. Impact of mutation density and heterogeneity on papillary thyroid cancer clinical features and remission probability [J]. Thyroid, 2019, 29(2): 237-251.
10	Liu R, Bishop J, Zhu G, et al. Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality [J]. JAMA Oncol, 2017, 3(2): 202-208.
11	Bournaud C, Descotes F, Decaussin-Petrucci M, et al. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma [J]. Eur J Cancer, 2019, 108: 41-49.
12	Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma [J]. Cell, 2014, 159(3): 676-690.
13	Mayakonda A, Lin DC, Assenov Y, et al. Maftools: efficient and comprehensive analysis of somatic variants in cancer [J]. Genome Res, 2018, 28(11): 1747-1756.
14	Chmielik E, Rusinek D, Oczko-Wojciechowska M, et al. Heterogeneity of thyroid cancer [J]. Pathobiology, 2018, 85(1-2): 117-129.
15	Schopper HK, Stence A, Ma D, et al. Single thyroid tumour showing multiple differentiated morphological patterns and intramorphological molecular genetic heterogeneity [J]. J Clin Pathol, 2017, 70(2): 116-119.
16	Mroz EA, Rocco JW. MATH, a novel measure of intratumorV genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma [J]. Oral Oncol, 2013, 49(3): 211-215.
17	Ma D, Jiang YZ, Liu XY, et al. Clinical and molecular relevance of mutant-allele tumor heterogeneity in breast cancer [J]. Breast Cancer Res Treat, 2017, 162(1): 39-48.
18	Pereira B, Chin SF, Rueda OM, et al. Erratum: The somatic mutation profiles of 2, 433 breast cancers refine their genomic and transcriptomic landscapes [J]. Nat Commun, 2016, 7: 11908.
19	Mroz EA, Tward AD, Pickering CR, et al. High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma [J]. Cancer, 2013, 119(16): 3034-3042.
20	Tufano RP, Teixeira GV, Bishop J, et al. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis [J]. Medicine (Baltimore), 2012, 91(5): 274-286.
21	Wang Z, Chen JQ, Liu JL, et al. Clinical impact of BRAF mutation on the diagnosis and prognosis of papillary thyroid carcinoma: a systematic review and meta-analysis [J]. Eur J Clin Invest, 2016, 46(2): 146-157.
22	Colombo C, Muzza M, Proverbio MC, et al. Impact of mutation density and heterogeneity on papillary thyroid cancer clinical features and remission probability [J]. Thyroid, 2019. 29(2): 237-251.
23	Colombo C, Muzza M, Proverbio MC, et al. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience [J]. JAMA Otolaryngol Head Neck Surg, 2013, 139(11): 1164-1170.
24	Yin DT, Yu K, Lu RQ, et al. Clinicopathological significance of TERT promoter mutation in papillary thyroid carcinomas: a systematic review and meta-analysis [J]. Clin Endocrinol (Oxf), 2016, 85(2): 299-305.
25	Kim TH, Kim YE, Ahn S, et al. TERT promoter mutations and long-term survival in patients with thyroid cancer [J]. Endocr Relat Cancer, 2016, 23(10): 813-23.
26	Penna GC, Pestana A, Cameselle JM, et al. TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma [J]. Endocrine, 2018. 61(3): 489-498.
27	Insilla AC, Proietti A, Borrelli N, et al. TERT promoter mutations and their correlation with BRAF and RAS mutations in a consecutive cohort of 145 thyroid cancer cases [J]. Oncol Lett, 2018, 15(3): 2763-2770.
28	Vuong HG, Duong UN, Altibi AM, et al. A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma [J]. Endocr Connect, 2017, 6(3): R8-R17.
29	Kim TH, Ki CS, Kim HS, et al. Refining dynamic risk stratification and prognostic groups for differentiated thyroid cancer with tert promoter mutations [J]. J Clin Endocrinol Metab, 2017, 102(5): 1757-1764.
30	Moon S, Song YS, Kim YA, et al. Effects of coexistent BRAF(V600E) and TERT promoter mutations on poor clinical outcomes in papillary thyroid cancer: A meta-analysis [J]. Thyroid, 2017, 27(5): 651-660.
31	Vuong HG, Altibi AMA, Duong UNP, et al. Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis [J]. Clin Endocrinol (Oxf), 2017. 87(5): 411-417.
32	Yoo SK, Lee S, Kim SJ, et al. Comprehensive analysis of the transcriptional and mutational landscape of follicular and papillary thyroid cancers [J]. PLoS Genet, 2016, 12(8): e1006239.
33	曹星月, 武晓泓. 基因拷贝数异常在甲状腺癌诊断和预后判断中的应用进展[J]. 国际内分泌代谢杂志, 2019, 39(1): 29-33.

?	例数	年龄		性别		临床分期				BRAF基因型
?	例数	<45岁	≥45岁	男	女	Ⅰ	Ⅱ	Ⅲ	Ⅳ	野生型	突变型
高MATH组	147	63	84	36	111	83	17	37	10	55	92
低^MATH组	205	80	125	57	148	99	23	50	33	73	132
χ^2值	?	0.521		0.484		7.19				0.121
P值	?	0.47		0.487		0.066				0.728

?	例数	年龄		性别		临床分期				BRAF基因型
?	例数	<45岁	≥45岁	男	女	Ⅰ	Ⅱ	Ⅲ	Ⅳ	野生型	突变型
高MATH组	147	63	84	36	111	83	17	37	10	55	92
低^MATH组	205	80	125	57	148	99	23	50	33	73	132
χ^2值	?	0.521		0.484		7.19				0.121
P值	?	0.47		0.487		0.066				0.728

[1]	Tiantian Chen, Xiaodong Wang, Haiyan Yu. Pregnancy outcome of twin pregnancy with Gitelman syndrome: a case report and literature review [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 559-568.
[2]	Xiaoman Zhang, Xiaoqiu Ma, Zhengju Xu, Chunyu Zhang, Caiting He. Effect of drug-resistant mutations in reverse transcriptase region of hepatitis B virus on the level of serum hepatitis B surface antigen [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2023, 17(05): 324-332.
[3]	Yonghao Li, Xuefei Gao, Tiantian Guo, Jin Zhang, Caizhen Zhang, Jing Liu. Advances in the research of mechanisms related to obesity combined with thyroid carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(04): 311-315.
[4]	Yutao Yuan, Jinlin Xing, Kefei Xie, Kai Yin. Correlation between CT findings and BRAF^V600E gene mutation and central lymph node metastasis in papillary thyroid carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 611-614.
[5]	Zhanbin Cui, Junli Qiao, Lili Zhang, Mingqiang Han. Correlation between urinary iodine levels and stratified risk of recurrence in patients with papillary thyroid cancer after surgery [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 615-618.
[6]	Yao Chen, Boqun Xu, Zhihui Gao. Efficacy and safety of modified intermediate upper approach radical resection in the treatment of thyroid cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 619-622.
[7]	Zhenjian Jiang, Ming Jiang, Dali Huang. The expression and prognostic value of TK1 and Ki67 proteins in differentiated thyroid carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 623-626.
[8]	Hui Huang, Xinqiang Zhu. Efficacy and influencing factors of ¹³¹I in the treatment of differentiated thyroid carcinoma under 45 years old [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 627-630.
[9]	Lichao Fan, Jinying Guo, Xin Chen. The significance of detection of wild-type RET and RET/PTC fusion gene for lymph node dissection in the central region of papillary thyroid carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 631-635.
[10]	Cheng Xu, Lulu Wang, Shaohua Wang. Application of eluent thyroglobulin in metastatic lymph nodes of thyroid papillary carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 701-704.
[11]	Yi Wang, Sizhe Xu, Zhangxia Ren. Effect of endoscopic unilateral thyroid lobectomy via thoracic breast approach and open surgery on postoperative recovery in patients with differentiated thyroid cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(05): 542-545.
[12]	Rong Zhang, Hongzhen Qin, Xiaodong Yang, Shuang Liu, Mingfeng Liu, Xiutang Cao. Clinical application and observation of postoperative rehabilitation exercise of patients with differentiated thyroid cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(04): 439-442.
[13]	Hongtao Jia, Qingqiang Ni, Zetao Yu, Jun Lu, Hong Chang. Treatment and prognosis of spontaneous rupture hemorrhage of liver cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(04): 408-412.
[14]	Runzhi Chen, Dongmei Yang, Huiting Xu. PD-1 combined with surufatinib for the treatment of metastatic colon cancer with microsatellite stability and BRAF V600E mutation: A case report and review [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(05): 431-435.
[15]	Lin Liu, Qishan Zhang, Manqian Liao, Yurong Chen, Bei Li, Yucheng He, Shengtao Tang. HTRA1-related autosomal dominant cerebral small vessel disease: a family report and literature review [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2023, 17(04): 379-385.

Please choose a citation manager

Content to export